Download PDF
Thorac Cardiovasc Surg 2004; 52(4): 225-229
DOI: 10.1055/s-2004-821078
Original Cardiovascular

© Georg Thieme Verlag KG Stuttgart · New York

Autologous Fibrin Glue Reinforced by Platelets in Surgery of Ascending Aorta[*]

J. T. Christenson1 , A. Kalangos1
  • 1Department of Cardiovascular Surgery, University Hospital of Geneva, Geneva, Switzerland
Further Information

Publication History

Received January 5, 2004

Publication Date:
04 August 2004 (online)

   Permissions and Reprints All articles of this category

Abstract

Objectives: Fibrin sealants are popular for the improvement of perioperative hemostasis and reducing blood transfusion needs. Biological glues prepared from pooled human donor plasma have an inherent risk of transmission of blood-borne disease and are quite expensive to use. A system for the production of autologous fibrin sealant reenforced by platelets has been developed. Its efficacy, safety and economic benefits have been evaluated in a prospective, randomized study. Material: 20 consecutive patients undergoing replacement of the ascending aorta by the same surgical team had local application of either Tissucol™ (Group A) or autologous fibrin glue (Group B) for hemostasis. Results: No adverse effects of either glue were recorded. The volume of produced autologous fibrin glue was 25 cc PRP. Platelet yield was 72 %. The two groups were comparable. Efficacy was group comparable. Average cost for sealants in Group A was 470 ± 100 Euros compared to 273 Euros in Group B, p = 0.004. Conclusions: Autologous fibrin glue reenforced by autologous platelets can be safely produced in the operating room in a large volume, with an comparable efficacy at a lower cost than commercial sealants.

Key words

Surgery of ascending aorta - surgical glue - hemostasis - hemorrhage - costs

1 Presented at 4th joint meeting of the German, Austrian and Swiss Societies for Thoracic and Cardiovascular Surgery, February 15 - 18, 2004, Hamburg, Germany

References

  • 1 Carless P A, Anthony D M, Henry D A. Systemic review of the use of fibrin sealant to minimize perioperative allogeneic blood transfusion.  Br J Surg. 2002;  89 695-703
    CrossrefPubMedSearch in Google Scholar
  • 2 Borst H G, Haverich A, Walterbusch G. et al . Fibrin adhesive: an important hemostatic adjunct in cardiovascular operations.  J Thorac Cardiovasc Surg. 1982;  84 548-553
    PubMedSearch in Google Scholar
  • 3 Mathew T L, Spotnitz W D, Kron I L. et al . Four years' experience with fibrin sealant in thoracic and cardiovascular surgery.  Ann Thorac Surg. 1990;  50 40-44
    PubMedSearch in Google Scholar
  • 4 Seguin J R, Picard E, Frapier J M, Chaptal P A. Aortic valve repair with fibrin glue for type A acute aortic dissection.  Ann Thorac Surg. 1994;  58 304-307
    PubMedSearch in Google Scholar
  • 5 Radosevich M, Goubran H A, Burnouf T. Fibrin sealant: scientific rationale, production methods, properties and current clinical use.  Vox Sang. 1997;  72 133-143
    CrossrefPubMedSearch in Google Scholar
  • 6 Jackson M R. Fibrin sealants in surgical practice: An overview.  Am J Surg. 2001;  182 (Suppl) 1S-7S
    PubMedSearch in Google Scholar
  • 7 Spotnitz W D. Commercial fibrin sealants in surgical care.  Am J Surg. 2001;  182 (Suppl) S8-14
    CrossrefPubMedSearch in Google Scholar
  • 8 Kawamura M, Sawafuji M, Watanabe M. et al . Frequency of transmission of human parvovirus B19 infection by fibrin sealant used during thoracic surgery.  Ann Thorac Surg. 2002;  73 1098-1100
    CrossrefPubMedSearch in Google Scholar
  • 9 Kjaergard H K, Trumbull H R. Vivostat system autologous fibrin sealant: preliminary study in elective coronary bypass grafting.  Ann Thorac Surg. 1998;  66 482-486
    CrossrefPubMedSearch in Google Scholar
  • 10 Man D, Plosker H, Winland-Brown J E. The use of autologous platelet-rich plasma (platelet gel) and autologous platelet-poor plasma (fibrin glue) in cosmetic surgery.  Plastic Reconstr Surg. 2001;  107 229-239
    CrossrefPubMedSearch in Google Scholar
  • 11 Fang W C, Helm R E, Krieger K H. et al . Impact of minimum hematocrit during cardiopulmonary bypass on mortality in patients undergoing coronary artery surgery.  Circulation. 1997;  96 (Suppl II) II-194-199
    PubMedSearch in Google Scholar
  • 12 Kjaergard H K, Fairbrother J E. Controlled clinical studies of fibrin sealant in cardiovascular surgery: a review.  Eur J Cardiothorac Surg. 1996;  10 727-733
    CrossrefPubMedSearch in Google Scholar
  • 13 Mankad P S, Codispoti M. The role of fibrin sealants in hemostasis.  Am J Surg. 2001;  182 21S-28S
    CrossrefPubMedSearch in Google Scholar
  • 14 Sellman M, Intonti M A, Ivert L. Reoperations for bleeding after coronary artery bypass procedures during 25 years.  Eur J Cardiothoracic Surg. 1997;  11 521-527
    PubMedSearch in Google Scholar
  • 15 Christenson J T, Reuse J, Badel P. et al . Autologous platelet sequestration in patients undergoing coronary artery bypass grafting. A prospective randomized study.  Eur J Cardiothorac Surg. 1996;  10 1083-1089
    CrossrefPubMedSearch in Google Scholar
  • 16 Spotnitz W D. Fibrin sealant in the United States: clinical use at the University of Virginia.  Thromb Haemost. 1995;  47 482-485
    PubMedSearch in Google Scholar
  • 17 Milne A A, Murphy W G, Reading S J, Ruckley C V. Fibrin sealant reduces suture line bleeding during carotid endarterectomy: a randomized trial.  Eur J Endovasc Surg. 1995;  10 91-94
    PubMedSearch in Google Scholar
  • 18 Schuele A M, Beierlein M S, Wendel H P. et al . Fibrin sealant, aprotinin, and immune response in children undergoing operations for congenital heart disease.  J Thorac Cardiovasc Surg. 1998;  115 883-889
    PubMedSearch in Google Scholar
  • 19 Tawes Jr R L, Sydorak G R, DuVall T B. Autologous fibrin glue: the last step in operative hemostasis.  Am J Surg. 1994;  168 120-122
    PubMedSearch in Google Scholar
  • 20 Pierce G F, Mustoe T A, Altrock B W, Deuel T F, Thomason A. Role of platelet derived growth factor in wound healing.  J Cell Biochem. 1991;  45 319-326
    CrossrefPubMedSearch in Google Scholar

1 Presented at 4th joint meeting of the German, Austrian and Swiss Societies for Thoracic and Cardiovascular Surgery, February 15 - 18, 2004, Hamburg, Germany

Dr. M. D., FETCS J. T. Christenson

Clinic for Cardiovascular Surgery, University Hospital

24 rue Micheli-du-Crest

1211 Geneva 14

Switzerland

Phone: + 41223727872

Fax: + 41 2 23 72 76 34

Email: jan.christenson@hcuge.ch